Abstract Details

Title Characterization of "Early-Start" Participants that Continued Receiving Donanemab in the TRAILBLAZER-ALZ 2 Long-Term Extension Period

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) LS2 - Late-breaking Science 2 (6:03 PM-6:09 PM)

Poster/Presentation
Number 004

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Curt P. Schreiber, MD (CPS Medical Solutions) PRESENTER	Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Schreiber has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Schreiber has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for eisai. Dr. Schreiber has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for lilly. Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for pfizer.
Traci Schilling	No disclosure on file
Erin G. Doty, MD (Eli Lilly and Company)	Dr. Doty has received personal compensation for serving as an employee of Eli Lilly and Company, USA. Dr. Doty has stock in Eli Lilly and Company, USA.
Fan Yang, PhD	Ms. Yang has nothing to disclose.
Shoichiro Sato, MD, PhD	Dr. Sato has received personal compensation for serving as an employee of Eli Lilly and Company. Dr. Sato has stock in Eli Lilly and Company.
Jennifer Zimmer, MD	Dr. Zimmer has received personal compensation for serving as an employee of Eli Lilly & Company. Dr. Zimmer has stock in Eli Lilly & Company.